Advertisement

Topics

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

13:06 EDT 22 Sep 2016 | SCRIP

A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race...

      

Related Stories

 

Original Article: Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

NEXT ARTICLE

More From BioPortfolio on "Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...